Shots:
- Royalty Pharma has acquired a royalty interest in Amgen’s Imdelltra from BeOne Medicines for ~$950M
- As per the deal, Royalty Pharma will acquire BeOne’s ~7% royalty on global Imdelltra sales for ~$950M, including $885M upfront and an option for BeOne to sell more for $65M within 12mos. The royalty, including shared sales above $1.5B annually, is expected to last through 2038–2041. BeOne retains China rights
- Imdelltra is a DLL3-targeting BiTE immunotherapy marketed by Amgen for extensive-stage small cell lung cancer (ES-SCLC)
Ref: Royalty Pharma | Image: Royalty Pharma and Amgen and Beone Medicine | Press Release
Related News:- Royalty Pharma Purchases Revolution Medicines’ Royalty Rights of Daraxonrasib for ~2B
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
